This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why CytomX Therapeutics (CTMX) Stock Might be a Great Pick
by Zacks Equity Research
CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Here's Why CytomX Therapeutics (CTMX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does CytomX Therapeutics (CTMX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for April 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 17th
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will CytomX Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor CytomX Therapeutics
Top Ranked Momentum Stocks to Buy for April 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd
CytomX & Astellas Collaborate to Develop Novel Cancer Therapy
by Zacks Equity Research
CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -43.64% and -47.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will CytomX Therapeutics (CTMX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.36% and -40.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CytomX Therapeutics (CTMX) Q2 Earnings Expected to Decline
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 41.51% and 116.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in CytomX Therapeutics.
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -26.19% and -23.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CytomX Therapeutics (CTMX) Q3 Earnings Expected to Decline
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.94% and 29.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Amgen Enters Into an Immuno-Oncology Partnership With CytomX
by Zacks Equity Research
Amgen (AMGN) has entered into a strategic immuno-oncology collaboration with CytomX to jointly develop a T-cell engaging bispecific probody.
Should CytomX Therapeutics (CTMX) Be On Your Radar Now?
by Zacks Equity Research
CytomX Therapeutics (CTMX) seems to be overlooked by shareholders as its favorable estimate revisions are not well reflected by its share price performance.
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.